CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis | Science Translational Medicine
A CALR mutant–targeted CAR T cell therapy selectively depletes mutant CALR+ cancer stem cells in vivo and in fibrotic human bone marrow organoids.
